4.8 Article

Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart

期刊

ADVANCED SCIENCE
卷 9, 期 11, 页码 -

出版社

WILEY
DOI: 10.1002/advs.202103672

关键词

antigenicity; immunogenicity; pegloticase; pharmacokinetics; polyethylene glycol; polyethylene glycol antibody; uricase

资金

  1. National Institutes of Health [R41 TR003255-01, R01DK124276-01]

向作者/读者索取更多资源

Protein therapeutics, especially those with PEG decoration, face challenges of short half-life and immunogenicity. The authors developed a poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) conjugate to improve the stability and immunogenicity of PEGylated proteins. The uricase-POEGMA conjugate demonstrated enhanced pharmacokinetics and reduced immunogenicity compared to traditional PEGylated proteins.
Protein therapeutics, except for antibodies, have a short plasma half-life and poor stability in circulation. Covalent coupling of polyethylene glycol (PEG) to protein drugs addresses this limitation. However, unlike previously thought, PEG is immunogenic. In addition to induced PEG antibodies, approximate to 70% of the US population has pre-existing anti-PEG antibodies. Both induced and preexisting anti-PEG antibodies result in accelerated drug clearance, reduced clinical efficacy, and severe hypersensitivity reactions that have limited the clinical utility of uricase, an enzyme drug for treatment for refractory gout that is decorated with a PEG corona. Here, the authors synthesize a poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) conjugate of uricase that decorates the protein with multiple polymer chains to create a corona to solve these problems. The resulting uricase-POEGMA is well-defined, has high bioactivity, and outperforms its PEG counterparts in its pharmacokinetics (PK). Furthermore, the conjugate does not induce anti-POEGMA antibodies and is not recognized by anti-PEG antibodies. These findings suggest that POEGMA conjugation may provide a solution to the immunogenicity and antigenicity limitations of PEG while improving upon its PK benefits. These results transcend uricase and can be applied to other PEGylated therapeutics and the broader class of biologics with suboptimal PK.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据